MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner reported a tax-withholding disposition of 23,301 shares of Common Stock on July 28, 2026. These shares were withheld by MiniMed Group to satisfy income tax withholding and remittance obligations tied to vesting Restricted Stock Units. After this withholding, Spooner directly holds 362,707 shares of Common Stock, including shares to be issued upon the vesting of one or more RSUs.
MiniMed Group, Inc. executive Chandrasena Gillian, SVP and Chief HR Officer, reported a tax-withholding disposition of 2,099 shares of Common Stock on 2026-07-28 at $17.67 per share. The shares were withheld by the company to satisfy income tax obligations related to RSU vesting, leaving 172,745 shares owned directly, including shares to be issued upon the vesting of one or more RSUs.
MiniMed Group, Inc. director Endicott David J. filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing shows no reported transactions and no listed holdings of MiniMed Group securities in the provided data.
MiniMed Group, Inc. director Linnea Burman has filed an initial Form 3 reporting status as an insider of the company. The filing shows no reported transactions or holdings, with zero shares listed for purchases, sales, exercises, gifts, tax withholding, or restructurings.
MiniMed Group, Inc. senior vice president and general counsel Courtney Nelson reported equity compensation grants of common stock on July 1, 2026. The Form 4 shows two awards totaling 22,057 and 60,730 shares, each recorded at $0.00 per share as compensation rather than open-market purchases.
Footnotes state these represent restricted stock units granted under the 2026 Long Term Incentive Plan. One grant vests in roughly equal one-third installments on the first, second and third anniversaries of the grant date, while the other vests on the third anniversary. Following these awards, the filing reports updated direct holdings of 138,146 and 116,089 common shares in the respective lines, including shares issuable upon RSU vesting and 296 shares acquired via the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. executive Gyurci John, VP and Chief Accounting Officer, reported an equity compensation grant rather than a market purchase or sale. He received 24,244 shares of Common Stock as a grant of restricted stock units under the 2026 Long Term Incentive Plan, with these RSUs vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date. Following this award, his directly held position is reported as 39,941 shares of common stock, which includes shares issuable upon vesting of one or more RSUs and 375 shares acquired through MiniMed’s 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. senior vice president and chief HR officer Gillian Chandrasena reported two equity compensation grants of common stock on July 1, 2026. Both transactions are coded as awards, not open‑market purchases or sales.
The filing shows one grant of 14,705 restricted stock units (RSUs) under the 2026 Long Term Incentive Plan that vest in approximately equal one‑third increments on the first, second and third anniversaries of the grant date. A second RSU grant of 29,483 shares vests on the third anniversary of the grant date. Following these awards, reported direct holdings include common stock and shares that will be issued as RSUs vest, as well as 891 shares acquired under the 2026 Employee Stock Purchase Plan on June 30, 2026.
Spooner Chad reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received equity-based compensation in the form of restricted stock units tied to common stock. He was granted 22,057 shares that vest in three equal annual installments and 94,550 shares that vest on the third anniversary of the grant date.
Both awards were granted at no cash cost per share and are part of the 2026 MiniMed Group, Inc. Long Term Incentive Plan. Following these grants, Spooner directly holds more than 360,000 shares of common stock, indicating this is a compensation-related increase rather than an open-market purchase.
MiniMed Group, Inc. reported that officer Ali Dianaty received two equity awards of common stock on July 1, 2026. The filing shows grants classified as restricted stock units under the 2026 Long Term Incentive Plan, covering 36,762 shares and 94,550 shares of common stock at no cash cost.
The RSUs tied to these awards vest over time, with one grant vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date, and another vesting on the third anniversary. Existing holdings also include shares to be issued upon vesting of prior RSUs and 600 shares acquired under the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received a grant of 297,618 restricted stock units (RSUs) of common stock at no cost, described as a grant, award or other acquisition under the company’s 2026 Long Term Incentive Plan.
The RSUs vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date, tying most of the benefit to future service and performance. Following this award, Que holds 916,099 shares of common stock, including shares expected to be issued upon vesting of one or more RSUs and 1,727 shares acquired through the 2026 Employee Stock Purchase Plan.